Definium Therapeutics reported a third quarter 2026 net loss of $51.0 million, or $0.46 per diluted share, outperforming analyst expectations of a $0.55 loss. The clinical-stage company remains pre-revenue, focusing its capital on the late-stage development of DT120 ODT, which is currently supported by a cash runway extended into 2030.
Key Highlights
- Management confirmed that the DT120 ODT NDA filing remains on track for the first half of 2027 following positive Phase 3 results in GAD and MDD.
- Cash, cash equivalents, and investments totaled $1.05 billion as of September 30, 2026, compared to $411.6 million at the end of 2025.
- Research and development expenses increased 48.9% year-over-year to $46.1 million, driven by the expansion of clinical programs and associated personnel costs.
- The reported net loss was partially offset by a $12.4 million non-cash gain related to the change in fair value of financing warrants.